12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

• 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% to $5.99 during Thursday's after-market session. The market value of their outstanding shares is at $204.2 million.
• Theriva Biologics (AMEX:TOVX) stock moved upwards by 17.68% to $0.53. The company's market cap stands at $3.8 million.
• iRhythm Technologies (NASDAQ:IRTC) stock increased by 13.42% to $159.0. The market value of their outstanding shares is at $4.4 billion. As per the press release, Q2 earnings came out today.
• Alphatec Holdings (NASDAQ:ATEC) shares rose 13.32% to $11.99. The market value of their outstanding shares is at $1.5 billion. As per the news, the Q2 earnings report came out today.
• Bio-Rad Laboratories (NYSE:BIO) stock moved upwards by 12.0% to $271.0. The market value of their outstanding shares is at $7.0 billion. The company's, Q2 earnings came out today.
• Cocrystal Pharma (NASDAQ:COCP) shares moved upwards by 8.67% to $1.88. The company's market cap stands at $16.9 million.

Losers

• Zynex (NASDAQ:ZYXI) shares fell 12.1% to $1.96 during Thursday's after-market session. The market value of their outstanding shares is at $75.2 million. As per the news, the Q2 earnings report came out today.
• Lyell Immunopharma (NASDAQ:LYEL) stock decreased by 10.85% to $10.6. The market value of their outstanding shares is at $231.1 million.
• Orchestra BioMed Hldgs (NASDAQ:OBIO) stock fell 10.14% to $2.75. The company's market cap stands at $119.5 million.
• Y-mAbs Therapeutics (NASDAQ:YMAB) stock decreased by 8.28% to $4.1. The company's market cap stands at $216.9 million.
• OPKO Health (NASDAQ:OPK) stock decreased by 7.82% to $1.18. The company's market cap stands at $1.0 billion. As per the news, the Q2 earnings report came out today.
• Moleculin Biotech (NASDAQ:MBRX) shares declined by 6.06% to $0.59. The market value of their outstanding shares is at $21.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.